Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care. The Company has pioneered stem cell research using human amniotic membrane to treat corneal surface conditions and developed Amniograft™, the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. The National Institute of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 130,000 human implants have been conducted using the Company’s patented Crotek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform.
Subsidiary of TissueTech Bio-Tissue, Inc., an ophthalmic biologic therapeutics company, has announced the introduction of two next-generation PROKERA Biologic Corneal Bandage devices.
TissueTech, Inc., the industry leader in regenerative tissue engineering, announced the completion of a $10 million round of growth equity financing from Ballast Point Ventures and River Cities Capital Funds.